Galectin-3 is a multifunctional carbohydrate-binding protein found in the nucleus, cytoplasm and the extracellular milieu. Nuclear galectin-3 expression is associated with cell proliferation, and its role in premRNA splicing has been suggested. In this report, we investigated the role of galectin-3 on cyclin D 1 gene expression, a critical inducer of the cell cycle and a potential oncogene in human cancer. We found that galectin-3 induces cyclin D 1 promoter activity in human breast epithelial cells independent of cell adhesion through multiple cis-elements, including the SP1 and CRE sites. We present evidence that galectin-3 induction of the cyclin D 1 promoter may result from enhancement/ stabilization of nuclear protein-DNA complex formation at the CRE site of the cyclin D 1 promoter. We also show that galectin-3 co-operates with, but does not depend on, pRb for cyclin D 1 promoter activation. The present study reveals a growth promoting activity of galectin-3 through cyclin D 1 induction, and suggests a novel function of nuclear galectin-3 in the regulation of gene transcription.
Introduction
Galectin-3 is a member of the b-galactosidase-binding gene family found abundantly in epithelial and immune cells. Galectin-3 is often highly expressed in human tumor cells and modulates a variety of cellular processes (Bresalier et al., 1997; Konstantinov et al., 1996; Lotan et al., 1994; Nangia-Makker et al., 1998; Raz et al., 1989) . Extracellular galectin-3 mediates cell migration, cell adhesion and cell -cell interactions, while intracellular galectin-3 regulates apoptosis (Akahani et al., 1997; Kim et al., 1999; Le Marer and Hughes, 1996; Sato and Hughes, 1992; Yang et al., 1996) . Galectin-3 is also found in the nucleus as a nuclear matrix protein and involved in pre-mRNA splicing (Dagher et al., 1995; Wang et al., 1995) . We have previously shown that galectin-3 overexpression causes changes in expression levels of cell cycle regulators, including cyclin D 1 (Kim et al., 1999) , suggesting a role for galectin-3 in the regulation of gene expression. Structurally, galectin-3 is composed of two distinct domains: an N-terminal domain containing proline and glycine rich sequences and a globular C-terminal domain containing a carbohydrate recognition site (Raz et al., 1989) . Galectin-3 contains four amino acid residues (NWGR) that are conserved in the BH1 domain of the bcl-2 gene family. Substitution of the Gly 182 residue with Ala in the NWGR motif of galectin-3 abrogates its anti-apoptotic function and its ability to modulate expression levels of cell cycle regulators (Akahani et al., 1997; Kim et al., 1999) .
The human cyclin D 1 gene, also known as PRAD1, D11S287 or BCL-1, is strongly implicated as an oncogene in several types of human tumors including B-cell lymphomas, squamous cell carcinomas of the head, neck and esophagus, and breast cancer (Motokura and Arnold, 1993) . Cyclin D 1 forms a complex with cyclin-dependent kinases (CDK4/6) and regulates progression of the early to mid G 1 phase of the cell cycle (Pines, 1995; Sherr, 1994) . Studies have suggested that cyclin D 1 expression is the rate limiting step for G 1 progression (Lukas et al., 1995; Resnitzky and Reed, 1995) . Growth factors activate signal transduction pathways, including the ras-raf-p42/p44MAPK cascade, phospholipid turnover, and p60 src pathways, resulting in activation of the cyclin D 1 promoter (Albanese et al., 1995; Lavoie et al., 1996; Lee et al., 1999; Watanabe et al., 1996a,b) . The cyclin D 1 promoter contains multiple binding sites for transcription factors, including AP-1, signal transducers and activators of transcription (STAT), nuclear factor kappa B (NF-kB), cAMP-responsive element binding protein (CREB)/activating transcription factor (AFT), E2F, and SP1 . Growth factor activation of the cyclin D 1 promoter is mediated largely by these elements (Guttridge et al., 1999; Hinz et al., 1999; Joyce et al., 1999; Matsumura et al., 1999; Nagata et al., 2001; Watanabe et al., 1996a) . However, studies demonstrated that growth factor signaling alone is not sufficient, and cell adhesion signaling is required for cyclin D 1 transcription (Le Gall et al., 1998; Zhu et al., 1996) . Cell adhesion-activated cyclin D 1 promoter appears to occur through focal adhesion kinase (Zhao et al., 1998) and integrin-linked kinase (ILK) involving CREB-dependent pathway (D'Amico et al., 2000) . In addition, the tumor suppressor protein pRB (retinoblastoma protein) was shown to be involved in cyclin D 1 regulation, through sequestration of E2F, an inhibitor of cyclin D 1 promoter activity, or by interaction with other transcription factors such as SP1, Ets, and Myc proteins (Albanese et al., 1995; Kim et al., 1992; Philipp et al., 1994; Watanabe et al., 1998) .
In the present study, we investigated the role of galectin-3 in the regulation of cyclin D 1 promoter activity. Here, we report that galectin-3 induces cyclin D 1 promoter activity independent of cell adhesion. Galectin-3 induction of cyclin D 1 promoter is mediated by multiple cis-elements including SP1 and CREB binding sites. Galectin-3 co-operates with, but does not depend on, pRB for cyclin D 1 promoter activation. We also present evidence that galectin-3 induction of cyclin D 1 promoter activity may result from enhancement/ stabilization of nuclear protein-DNA complex formation at the CRE site of the cyclin D 1 promoter.
Results

Galectin-3 activates cyclin D 1 promoter activity
Immunoblot analysis (Figure 1a) showed that cyclin D 1 protein expression is significantly upregulated in galectin-3 overexpressing BT549 cells (BT549-Galwt), but not in mutant galectin-3 overexpressing cells (BT549-Galm). To determine whether galectin-3 overexpression results in upregulation of cyclin D 1 expression at the transcriptional level, a luciferase reporter gene under the control of 964 bp cyclin D 1 promoter (7964CD1LUC) was introduced into control vector transfected (BT549neo), BT549-Galwt, and BT549-Galm cells. Cyclin D 1 promoter activity was *4-fold higher in BT549-Galwt cells compared to the level in BT549neo cells, whereas the cyclin D 1 promoter activity was comparable between BT549-Galm and BT549neo cells (Figure 1b) . These results showed that wild-type galectin-3 specifically upregulates cyclin D 1 promoter activity.
To exclude the possibility that increased cyclin D 1 promoter activity in BT549-Galwt cells results from clonal selection and/or long term cell culture with stable galectin-3 expression, we examined the role of galectin-3 in cyclin D 1 promoter activation by transient transfection into BT549 and MCF-7, both human breast carcinoma cell lines. Cyclin D 1 promoter activity was enhanced by galectin-3 in a dose-dependent manner; transient transfection of 1.5 mg galectin-3 expression plasmid enhanced cyclin D 1 promoter activity *10-fold in both BT549 (Figure 2a ) and MCF-7 (Figure 2b ) cells.
As a control experiment, an expression vector containing galectin-3 cDNA in a reverse orientation was introduced into BT549 cells. Galectin-3 expression (sense) vector, but not an anti-sense construct, induced cyclin D 1 promoter activity ( Figure 2c ). As an additional control experiment, the effects of galectin-3 expression on b-actin or luciferase reporter gene expression under thymidine kinase promoter with two copies of palindrome thyroid hormone receptor response element TRE (pTK-Pal-Luc, a gift from Dr JL Jameson at Northwestern University, Chicago, IL, USA) were also examined. There was no increase in b-actin expression or luciferase activity using the pTK-Pal-Luc construct when co-transfected with galectin-3 expression plasmid Lysates (10 mg/lane) of BT549neo, BT549-Galm, and BT549-Galwt were subjected to immunoblot analysis with an anti-cyclin D 1 , anti-galectin-3, or anti b-actin antibody. Detection of the antigen was performed using ECL. (b) BT549neo, BT549-Galm, and BT549-Galwt cells were co-transfected with 3 mg of luciferase reporter construct (7964CD1LUC) and 0.15 mg of the b-galactosidase expression plasmid (pMDV-lacZ) using FuGENE 6 reagent. Cells were harvested at 36 h after transfection and the luciferase activity in 1 mg of cell lysate was normalized to b-galactosidase activity. The luciferase activity in BT549neo cells was arbitrarily given as 1. The data represent the average of three separate transfection experiments. Error bars represent s.d. of the mean (data not shown). These control experiments further suggest that cyclin D 1 promoter activation was galectin-3 specific.
Galectin-3 activates cyclin D 1 promoter in the absence of cell adhesion It was previously shown that cell adhesion signaling is a pre-requisite for growth factor-induced cyclin D 1 expression and that cyclin D 1 gene transcription is downregulated following the loss of cell adhesion (Le Gall et al., 1998; Zhu et al., 1996) . Thus, we questioned whether galectin-3-induced cyclin D 1 expression is cell adhesion signaling-dependent. Immunoblot analysis showed that the cyclin D 1 protein level was significantly higher in suspension cultures of BT549-Galwt cells compared to those in suspension cultures of BT549-Galm and BT549neo cells (Figure 3a) . Similarly, cyclin D 1 promoter activity was *5-fold higher in suspension cultures of BT549-Galwt cells (Figure 3b ) than those of BT549-Galm or BT549neo cells, demonstrating that cyclin D 1 promoter activation by galectin-3 is independent of cell adhesion. We further confirmed cell adhesion-independent galectin-3-induction of cyclin D 1 promoter activity by transient transfection studies. The cyclin D 1 promoter activity was reduced *75% in suspension culture (using polyHEMA-coated dishes which prevents cell adhesion) compared to the monolayer culture of control MCF10A cells, a spontaneously immortalized 'normal' human breast epithelial cell line. However, less than a 30% decrease in cyclin D 1 promoter activity was detected in MCF10A cells when galectin-3 is transiently transfected (Table 1 ). In suspension cultures of MCF10A cells, galectin-3 enhanced cyclin D 1 promoter activity *3-fold (0.23 vs 0.71). Galectin-3 also effectively induced cyclin D 1 promoter activity in suspension cultures of breast carcinoma MCF-7 (1.23 vs 9.45) and BT549 (0.86 vs 3.05) cells. It should be noted that galectin-3 induction of cyclin D 1 promoter activity in breast carcinoma cells was even greater in the absence of cell adhesion than in the presence of cell adhesion, suggesting that additional genetic changes in cancer cells may synergize with galectin-3 to further enhance cyclin D 1 promoter activity in the absence of 
Mutational analysis of the human cyclin D 1 promoter activity
To determine the cis-element(s) in the cyclin D 1 promoter region responsive to galectin-3, we transfected luciferase reporter constructs containing various lengths of the cyclin D 1 promoter (Figure 4 ) into BT549neo, BT549-Galwt, and BT549-Galm cells.
Promoter activity of 7163CD1LUC was comparable to 71745CD1LUC, 71093CD1LUC or 7964CD1LUC (data not shown). Further deletion of E2F binding sites (7141CD1LUC) or mutation in E2F binding site (7163E2F*CD1LUC) did not reduce the luciferase activity, as shown in Figure 4 . When the SP1 sites were deleted (766CD1LUC), the promoter activity decreased to less than half of 7141CD1LUC activity in BT549-Galwt cells. However, 766CD1LUC activity was still significantly higher in BT549-Galwt cells than those in BT549neo and BT549-Galm cells. This suggests that galectin-3-induced cyclin D 1 promoter activity significantly depends on the SP1 sites, and that additional cis-element(s) downstream of SP1 also play a role in galectin-3 induction of cyclin D 1 promoter activity.
The cyclin D 1 promoter contains a CRE site downstream of the SP1 sites. CREB binding was recently shown to mediate integrin-linked kinaseinduced cyclin D 1 promoter activity (D'Amico et al., 2000) , suggesting that the CRE site is critical for cell adhesion-mediated cyclin D 1 promoter activation. To examine the role of this CRE element for galectin-3 regulation of cyclin D 1 promoter, 735CD1LUC lacking CRE site was transfected into BT549 neo, BT549-Galwt and BT549-Galm cells. Further deletion of the CRE site in the cyclin D 1 promoter almost completely abolished cyclin D 1 promoter induction by galectin-3. These results showed that SP1 and CRE elements are largely responsible for galectin-3 induction of cyclin D 1 promoter activity.
Galectin-3 co-operates with pRb for cyclin D 1 promoter activation
Cyclin D 1 -associated kinase complex phosphorylates and inactivates pRb (Goodrich et al., 1991; Weinberg, 1995) . Interestingly, although pRb is not a transcription factor, pRb expression was shown to activate cyclin D 1 promoter in murine fibroblast cell line NIH3T3 and the human trophoblast cell line JEG-3, suggesting a negative feedback regulation loop between pRb and cyclin D 1 (Watanabe et al., 1998) . Since our (b) BT549neo, BT549-Galm, and BT549-Galwt cells were cotransfected with 3 mg of luciferase reporter construct (7964CD1LUC) and 0.15 mg of the b-galactosidase expression plasmid (pMDV-lacZ) using FuGENE 6 reagent. Next day, cells were trypsinized and cultured in suspension for an additional 24 h before harvest for luciferase activity assay. The luciferase activity in 1 mg of cell lysate was normalized to b-galactosidase activity. The data represent the average of three separate transfection experiments. Error bars represent s.d. of the mean MCF10A, MCF-7, and BT549 cells were transiently transfected for 16 h with 3 mg of 7964CD1LUC, 0.15 mg of pMDV-lacZ, and 0.5 mg of either galectin-3 expression vector (pCMV-Gal3) or control vector (pCMV-neo). Cells were trypsinized and cultured in a regular plate or in suspension for an additional 24 h before luciferase activity assay. The luciferase activity in monolayer culture of cells cotransfected with pCMV-neo was arbitrarily given as 1. Data represents the average+s.d. of six independent transfection experiments previous study revealed that stable overexpression of galectin-3 upregulates pRb expression in BT549 cells (Kim et al., 1999) , we asked if pRb is involved in galectin-3 regulation of cyclin D 1 in human breast epithelial cells. Transient transfection of 0.5 mg pRb expression vector (pCMV-Rb) alone induced cyclin D 1 promoter activity 2 -4-fold ( Figure 5 ). Similarly, transient transfection of 0.5 mg galectin-3 expression vector (pCMV-Gal3) enhanced cyclin D 1 promoter activity 3 -4-fold without detectable pRb upregulation (Of note, * in Figure 5 indicates nonspecific bands recognized by anti-Rb antibody). These results showed that pRb upregulates cyclin D 1 promoter activity in human breast epithelial BT549 cells similar to murine fibroblasts and human trophoblast cells. These results also showed that pRb is unlikely to be required for galectin-3 upregulation of cyclin D 1 promoter activity. When increasing amounts of pRb expression vector were transfected together with 7964CD1LUC reporter construct and galectin-3 expression vector, the cyclin D 1 promoter activity further increased (Figure 5a ). In a reciprocal experiment, when increasing amounts of galectin-3 expression vector were transfected together with 7964CD1LUC reporter construct and pRb expression vector, the cyclin D 1 promoter activity also further increased (Figure 5b ). The cyclin D 1 promoter induction by galectin-3 and pRb was additive, not synergistic. These results suggest that pRb and galectin-3 cooperate for cyclin D 1 promoter activation, but not necessarily depend on each other.
Galectin-3 enhances nuclear protein binding to the CRE site of the cyclin D 1 promoter
The present study showed that galectin-3 activates cyclin D 1 promoter even in the absence of cell adhesion signaling, possibly through SP1 and CRE sites. Since a recent study suggests that the CRE site mediates cell adhesion-regulated cyclin D 1 promoter activity (D'Amico et al., 2000), we questioned whether galectin-3 enhances CRE-mediated cyclin D 1 promoter activation, which compensates for a decrease in cell adhesion signaling. To this end, we examined whether nuclear proteins from BT549-Galwt cells bind more effectively to the cyclin D 1 CRE site compared to nuclear proteins from BT549neo cells. Nuclear proteins formed two major complexes (band A and B) with a radiolabeled double-stranded oligonucleotide containing the cyclin D 1 CRE site in the presence of 100-fold molar excess of non-specific competitor poly(dI-dC) ( Figure 6 ). Both complexes were competed out by 10-fold molar excess of unlabeled CRE oligonucleotides, indicating that these binding were CRE sequence specific. The density of these bands was significantly enhanced when nuclear extract of BT549-Galwt was used.
To determine the role of galectin-3 in nuclear protein binding to the CRE sequence, nuclear proteins were pre-incubated with anti-galectin-3 antibody prior to the binding reaction. The density of band B was drastically reduced by anti-galectin-3 antibody (*10-fold as quantified using Biorad Quantity One program), whereas incubation with preimmune serum had no detectable effect on the DNA-protein complex formation (Figure 6b ). These results suggest that galectin-3 enhances transcription factor complex binding to the CRE site, and anti-galectin-3 antibody binding to galectin-3 disrupted nuclear protein/DNA complex formation (especially band B) at the CRE site. To further confirm this, we examined the effect of recombinant galectin-3 protein on nuclear protein binding activity at the CRE site. The purity of The luciferase reporter constructs were transfected into BT549-neo, BT549-Galwt, and BT549-Galm cells. Cells were harvested and analysed for luciferase activity at 48 h after transfection. The luciferase activity in 1 mg of cell lysate was normalized to b-galactosidase activity. The luciferase activity of 7163CD1LUC1 in BT549neo cells was arbitrarily given as 1 recombinant galectin-3 protein was assured by polyacrylamide-SDS gel electrophoresis/Coomassie blue staining and immunoblot analysis (data not shown). Recombinant galectin-3 protein alone had no DNA binding activity at the cyclin D 1 CRE oligonucleotide (data not shown). However, when the effect of Figure 5 Galectin-3 co-operates with, but does not depend on, pRb for cyclin D 1 promoter activation. BT549 cells were transfected with 3 mg of 7964CD1LUC, 0.15 mg of the b-pMDV-lacZ, and the indicated combination of pCMV-Gal3 and pCMV-Rb plasmids (mg). The luciferase activity in 1 mg of cell lysate was normalized to b-galactosidase activity. The luciferase activity without galectin-3 and pRb plasmid transfection was arbitrarily given as 100. The pRb and galectin-3 protein levels after transfections were detected by immunoblot analysis (lower panels). The asterisk indicates a nonspecific band recognized by anti-Rb antibody (Santa Cruz Biotechnology) Figure 6 Galectin-3 enhances/stabilizes nuclear protein binding to the CRE site. (a) One or two mg of nuclear extracts prepared from BT549neo and BT549-Galwt cells were incubated with 0.2 ng of 32 P-dCTP-labeled double-stranded (ds) oligonucleotides containing the CREB binding site of the cyclin D 1 promoter in the presence of 100-fold molar excess of non-specific competitor poly(dI-dC), and subjected to mobility shift assay as described in Materials and methods. As a specific competitor, 10-fold molar excess of cold probe was added to reaction. Protein-DNA complexes were separated on a 5% non-denaturing polyacrylamide gel at 100 V for 2 h. Arrows indicate nuclear protein/CRE complexes (band A and B). (b) Equal amount of nuclear proteins prepared from BT549-Galwt cells were incubated with increase amounts of rat monoclonal anti-galectin-3 (Lanes 2 -4) or pre-immune serum (Lane 5). Complexes were resolved on a 5% polyacrylamide gel at 100 V for 2.5 h. (c) The 32 P-labeled oligonucleotides containing the CRE site were incubated with 2 mg of nuclear proteins from BT549 cells in the presence or absence of 1 mg of purified recombinant galectin-3 proteins (rGal-3). The complexes were resolved in 6% polyacrylamide gel at 100 V for 2.5 h. Arrows indicate the band A and B complexes. Of note, the additional band migrating between the band A and B is a non-specific band whose intensity and existence varied among experiments recombinant galectin-3 protein on BT549 nuclear protein binding to the CRE site was tested, *60% enhancement of band B formation (as quantified using Biorad Quantity One program) was observed ( Figure  6c ), further suggesting a role for galectin-3 in protein/ DNA complex formation at the CRE site. We also examined whether galectin-3 has any effect on nuclear protein binding to the SP1 site. Although mutational analysis of the human cyclin D 1 promoter clearly showed significance of the SP1 site for galectin-3 induction of cyclin D1 promoter activity (Figure 4) , we found no detectable difference in protein-DNA complex formation using oligonucleotides containing SP1 sites only (data not shown). Taken together, the present study suggests that nuclear galectin-3 may enhance/stabilize transcription factor binding to the CRE site in the cyclin D1 promoter, which then promotes the transactivation functions of transcription factors such as CREB and SP1. This notion is consistent with the previous reports that galectin-3 is a nuclear matrix protein and its expression in the nucleus is associated with cell proliferation (Openo et al., 2000) . We also confirmed galectin-3 expression in the nucleus of BT549-Galwt cells by immunofluorescence study (Figure 7 ). Galectin-3 protein was evenly detected in the nucleus and the cytoplasm in logarithmically growing BT549-Galwt cell (Figure 7a ). To confirm that galectin-3 is expressed within the nucleus, galectin-3 stained cells were mounted with medium containing DAPI (4',6 diamidino-2-phenylindole, Vector Laboratory, CA, USA) which produces a blue fluorescence when bound to DNA (Figure 7b ). Confocal microscopic analysis from the same plane of focus revealed that galectin-3 and DNA staining co-localize inside the nucleus ( Figure  7c ). In contrast, no detectable galectin-3 expression was found in the nucleus of quiescent BT549-Galwt cells cultured in serum-free medium for 48 h (Figure 7d) , suggesting a correlation between nuclear galectin-3 expression and cyclin D 1 expression during cell proliferation.
Discussion
The present study showed that galectin-3 upregulates cyclin D 1 promoter activity, a critical inducer of the cell cycle and a potential oncogene in human cancer (Lukas et al., 1995; Motokura and Arnold, 1993; Pines, 1995; Resnitzky and Reed, 1995; Sherr, 1994) , revealing a part of growth promoting/oncogenic action of galectin-3. Although galectin-3 does not directly bind to the cis-element of the cyclin D 1 promoter, the present study suggests a role for nuclear galectin-3 in the regulation of cyclin D 1 promoter through enhancement/stabilization of CRE-associated complex formation. This notion is consistent with recent reports that the cellular expression of galectin-3 is proliferation-dependent (Kadrofske et al., 1998; Openo et al., 2000) . While the galectin-3 protein was predominantly cytoplasmic in senescent human fibroblast cells, it was found in both the nucleus and the cytoplasm of proliferating cells (Openo et al., 2000) . Similarly, we showed that the galectin-3 protein is found in the nucleus of proliferating, but not quiescent, human breast epithelial cells.
Vascular endothelial growth factor-induced cyclin D 1 promoter activity was shown to be regulated by a dual system. One, mediated by SP1, is inducible in the G 1 phase, while the other, mediated by CREB, is constitutively active when cultured in monolayer (Nagata et al., 2001) . The integrin-linked kinase was shown to activate the CRE-dependent pathway for cyclin D 1 transcription. Thus, it appears that CREB mediates cell adhesion-dependent cyclin D 1 transcription, a pre-requisite for cyclin D 1 transcription, and SP1 mediates growth factor-induced cyclin D 1 transcription. Interestingly, the present study showed that galectin-3 induction of cyclin D 1 promoter activity also involves both SP1 and CREB pathways. The ability of galectin-3 to enhance both the SP1 and CREB pathways may explain how galectin-3 effectively induces cyclin D 1 expression in the absence of cell adhesion. Figure 7 Galectin-3 is expressed in the nucleus of proliferating, but not quiescent, human breast epithelial cells. BT549-Galwt cells (a -c) were cultured on a cover slip with serum-containing medium for 48 h, washed with PBS three times, fixed with 3.7% formaldehyde in PBS for 15 min, washed with PBS-S (PBS containing 0.1% saponin), and then stained with rat anti-galectin-3 antibody followed by incubation with FITC-conjugated secondary antibodies and with anti-fade mounting medium containing 1.5 mg/ml DAPI (Vector Laboratory, CA, USA). Galectin-3 protein was shown in green (a), the nuclei stained with DAPI shown in blue (b), and nuclear galectin-3 shown in light blue in the confocal mode from the same plane of focus with a Zeiss LSM microscope (c). (d) BT549-Galwt cells were cultured on cover slip with serum free medium for 48 h, and stained with rat anti-galectin-3 antibody as described above At present, it is unclear how galectin-3 co-operates with pRb for cyclin D 1 promoter activation. pRB induction of cyclin D 1 was suggested to occur through sequestration of E2F, an inhibitor of cyclin D 1 promoter activity, or by interaction with other transcription factors such as SP1 (Watanabe et al., 1998) . Galectin-3 effectively induced cyclin D 1 promoter activity for both 7163CD1LUC and 7163FCD1LUC which contains a mutation in the E2F site that abolished E2F binding (Figure 4) . Thus, it is unlikely that galectin-3 activation of cyclin D 1 involves pRB-E2F pathway. Galectin-3 together with pRb may stabilize transcription factor complexes, including CREB, SP1 and others, resulting in transactivation of their transcription factor function.
The present study suggests a novel function of nuclear galectin-3 in the regulation of gene transcription. Galectin-3, a nuclear matrix protein, appears to enhance/stabilize transcription factor binding to the cis-elements of the cyclin D 1 promoter, including CRE and possibly SP1 sites. Since CRE and SP1 sites are often found in the promoter region of many genes, galectin-3 may also modulate transcription of other genes. In fact, our previous study showed that galectin-3 overexpression results in changes in expression levels of other cell cycle regulators. Galectin-3 upregulates expression of cyclin A, p21 WAF1/CIP1 and p27 KIP1 , whereas it downregulates cyclin E expression (Kim et al., 1999) . These changes may result from galectin-3 regulation of transcription factor complexes (enhancer and/or silencer complexes). It is equally possible that many of these effects are indirect. Galectin-3 mediated cyclin D 1 upregulation may have subsequent effects on expression levels of other cell cycle regulators. It was previously shown that cyclin D 1 overexpression alone is sufficient to trigger cell cycle transition involving changes in expression levels of other cell cycle regulators (Bienvenu et al., 2001; Latella et al., 2001) . At present, the generality and specificity of galectin-3 regulation of gene transcription and its direct and indirect effects remain to be investigated.
We and others have previously shown that galectin-3 inhibits apoptosis induced by a variety of stimuli including staurosporine, cisplatin, genistein, and anoikis (apoptosis induced by the loss of cell adhesion) (Akahani et al., 1997; Kim et al., 1999; Lin et al., 2000; Matarrese et al., 2000; Matarresea et al., 2000; Yang et al., 1996) . Galectin-3 inhibition of anoikis involves cell cycle arrest at an anoikis-insensitive point (late G 1 ) through modulation of gene expression and the activities of cell cycle regulators (Kim et al., 1999) . Galectin-3 translocation to the nucleus and its phosphorylation are required for induction of cyclin D 1 expression and inhibition of anoikis (Yoshii et al., 2002) . However, galectin-3 regulation of cyclin D 1 in the nucleus is unlikely to be a common mechanism for apoptosis regulation. Following a variety of apoptotic stimuli, galectin-3 translocates to the perinuclear membrane and prevents mitochondrial damage and cytochrome c release, thereby effectively protecting cells against apoptosis induced by agents working through different apoptosis initiation pathways (Yu et al., 2002) . Likewise, in quiescent cells cultured in serum-free medium, galectin-3 translocates to the perinuclear membrane and inhibits apoptosis (Figure 7d and (Yu et al., 2002) ). Thus, galectin-3 induction of cyclin D 1 is likely to be associated with its growth promoting activity and have effects on only a subset of apoptotic processes where cell cycle regulation is critical (e.g., anoikis).
Materials and methods
Cell culture
The human breast carcinoma cell line BT549 was obtained from Dr EW Thompson (Georgetown University Medical Center). Establishment of neo-resistant control vector transfected BT549 (BT549neo), galectin-3 transfected BT549 (BT549-Galwt), and mutant galectin-3 expressing BT549 (BT549-Galm) was previously described (Akahani et al., 1997; Kim et al., 1999) . The mutant galectin-3 protein was generated by substitution of the Gly 182 residue in the NWGR motif with Ala (Akahani et al., 1997; Kim et al., 1999) . BT549 cells were cultured in RPMI1640 with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin (50 units/ml). MCF7 cells, a human breast carcinoma cell line, were cultured in DMEM/F12 with 10% donor calf serum, 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin (50 units/ml). MCF10A cells, a spontaneously immortalized 'normal' breast epithelial cell line, were cultured in DMEM/F12 medium supplemented with 5% horse serum, 0.5 mg/ml hydrocortisone, 10 mg/ml insulin, 20 ng/ml EGF, 0.1 mg/ml cholera enterotoxin, 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 0.5 mg/ml fungizone in a 95% air and 5% CO 2 incubator at 378C.
Suspension culture
PolyHEMA (polyhydroxyethylmethacrylate, purchased from Aldrich Chemical Co., WI, USA) was solubilized in methanol (50 mg/ml) and diluted in ethanol to a final concentration of 10 mg/ml. To prepare polyHEMA-coated dishes, 4 ml of polyHEMA solution was placed in 100-mm petri dishes and dried in a tissue culture hood. The polyHEMA coating was repeated twice, followed by three washes with PBS. Suspension culture was maintained in polyHEMA-coated 100-mm dishes in a 95% air and 5% CO 2 incubator.
Plasmid and transient transfection
The reporter constructs of human cyclin D 1 promoter 71745CD1LUC, 71093CD1LUC, 7964CD1LUC, 7163CD1LUC, 7163E2FCD1LUC, and 766CD1LUC were previously described (Albanese et al., 1995; Watanabe et al., 1996a Watanabe et al., , 1998 . The 7141CD1LUC was constructed by partial digestion of 7163CD1LUC with NarI and Klenow treatment, followed by SmaI digestion and self-ligation. The 735CD1LUC construct was created from 7163CD1LUC by PCR using primers CCTTATGCAGTTGCTCTCCAGCGG-TTCA and GGACTACCCGGGAGTTTTGTTGAAGTTG-CA. Cells were transfected with 6 mg cyclin D 1 reporter plasmid and 0.2 mg b-galactosidase expression plasmid pMDV-lacZ in the presence or absence of increasing amounts of galectin-3 expression plasmid pCMV-Gal3 (Akahani et al., 1997) or pRb expression plasmid pCMV-RB (a gift from Dr Y-HP Lee at the University of Texas Health Science Center at San Antonio). PCRII plasmid DNA (Invitrogen, CA) was used to adjust equal amounts of DNA for each transfection. Transfection was performed using FuGENE 6 reagent (Roche Molecular Biochemicals, Germany) according to manufacturer's protocol. The transfection efficiency was normalized by b-galactosidase activity. To measure cyclin D 1 promoter activity in the absence of cell adhesion, cells were washed with PBS and trypsinized 16 -24 h after transient transfection. One-half of the cells were cultured in regular plates and the other half were cultured using polyHEMA-coated plates. Cells were cultured for an additional 24 h and harvested for analysis.
Luciferase/b-galactosidase activity assay
Luciferase and b-galactosidase activity were assayed using Luciferase assay kit (Promega, WI, USA) and Galacto-Light kit (Tropix Inc., CA, USA) and measured with a luminometer (Promega, Turner TD-20e). The Luciferase activity was normalized to b-galactosidase activity and total protein determined by BCA protein assay kit (Pierce, IL, USA). The data are representative of at least three independent experiments.
Immunoblot analysis
Cells were lysed in SDS lysis buffer (2% SDS, 125 mM TrisHCl, pH 6.8, 20% Glycerol). The lysates were boiled for 5 min and then clarified by a 20-min centrifugation at 48C. Protein concentration was measured using BCA protein assay reagent (Pierce, IL, USA). Equal amounts of protein samples in SDS sample buffer (1% SDS, 62.5 mM Tris-HCl, pH 6.8, 10% Glycerol, 5% b-mercaptoethanol, 0.05% Bromophenol Blue) were boiled for 5 min and subjected to reducing SDS -PAGE. After electrophoresis, the proteins were transferred to a nitrocellulose membrane. The blot was then probed with anti-galectin-3, anti-cyclin D 1 (Calbiochem, CA, USA), or anti-pRb (Santa Cruz Biotech., CA, USA) antibody, and with the appropriate HRP-conjugated secondary antibodies. The antigen was detected using the ECL detection system according to the manufacturer's instruction (Pierce, IL, USA).
Nuclear extract preparation
Crude nuclear extracts were prepared as described (Lin et al., 1998) with slight modification. Cells were washed with cold phosphate buffer and resuspended in 5 volumes of cold buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT, 0.5 mM PMSF). The cells were allowed to swell on ice and lysed by rapid extrusion through a 26 1 2 G needle. Samples were centrifuged and the pelleted nuclei were extracted in cold buffer C (20 mM HEPES, pH 7.9, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, 0.5 mM PMSF, 0.5 mM DTT, 5 mg/ml leupeptin). Nuclear extracts were aliquoted and stored at 7708C until use.
Electrophoretic mobility shift assays
Double-stranded (ds) oligonucleotides containing the CREB binding site of the cyclin D 1 promoter were prepared by annealing two synthetic complementary oligomers (5'-AACA-ACAGTAACGTCACACGGACT-3' and 3'-TTGTTGTCA-TTGCAGTGTGCCTGATGT-5') in annealing buffer (0.5 M NaCl, 0.5 M Na 2 HPO 4 pH 8.0) at 958C for 5 min, 658C for 10 min and 48C for 2 h. The oligomers were labeled with [a-32 P]dCTP by Klenow fragment of DNA polymerase I.
Binding reactions were carried out for 20 min at room temperature in 10 mM HEPES pH 7.9, 80 mM KCl, 1 mM EDTA, 1 mM DTT, 4% Ficoll. Five micrograms of nuclear proteins were incubated with *0.2 ng of ds CRE oligonucleotides (375610 4 c.p.m.) in the presence of 100-fold molar excess of non-specific competitor poly(dI-dC). To confirm the specificity of protein binding to the CRE sequence, 5 mg of nuclear protein was incubated with 2 ng of unlabeled ds CRE oligonucleotides (10-fold molar excess of specific competitor) for 10 min prior to addition of *0.2 ng radiolabeled CRE probe. To examine the galectin-3 involvement in nuclear protein binding at the CRE oligonucleotides, pre-immune rabbit serum, anti-galectin-3 antibody, or recombinant galectin-3 protein was incubated with nuclear proteins on ice for 30 min before binding reaction to the CRE probe. Protein-DNA complexes were resolved on 5 or 6% nondenaturing polyacrylamide gels (acrylamide : bisacrylamide 19 : 1) electrophoresed in 0.56TBE (45 mM Tris-HCl, 45 mM Boric Acid, 0.5 mM EDTA). The gel was dried and autoradiographed.
Preparation of recombinant galectin-3 protein LB medium containing 10 mM MgCl 2 and 100 mg/ml ampicillin was inoculated with an overnight culture of HMS-174 transformed with the plasmid containing the human galectin-3 cDNA insert. When the bacterial cells were grown to an optical density of 0.5, IPTG (1 mM) was added. Cells were then incubated for an additional 4 h and harvested by centrifugation at 1250 g at 48C. The pellet was washed with PBS and suspended in 100 mM of ice-cold lysis buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris, pH 8, 0.241 unit/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ ml pepstatin, and 0.2 mM PMSF). The bacterial cells were disrupted by sonicator with multiple short bursts of maximum intensity (30s64) on ice. The lysate was centrifuged at 40 000 g for 20 min and the supernatants were passed through an asialofetuin affinity column (100622 mm inner diameter). The column was made by linking the asialofetuin to Affigel-15 (Bio-Rad, CA, USA) according to the manufacturer's protocol, and was well equilibrated in phosphate buffer (10 mM phosphate, 1 mM MgSO4, 0.2 mM PMSF, and 0.2% NaN 3 , pH 7.2). The column was washed with 3 -5 column volumes of phosphate buffer, and the bound protein was eluted with 0.2 M lactose. Eluted fractions were quantitated using BCA protein assay reagent (Pierce, IL, USA), analysed by SDS -PAGE and immunoblot analyses using an anti-galectin-3 antibody.
Abbreviations
The abbreviations used are: PBS, phosphate-buffered saline; CDK, cyclin-dependent kinase; CRE, cAMP-responsive element; CREB, cAMP-responsive element binding protein; SDS, sodium dodecyl sulfate; PMSF, phenylmethylsulfonyl fluoride; IPTG, isopropylthio-b-D-galactoside.
